Calidi Biotherapeutics, Inc. 8-K

What Happened
Calidi Biotherapeutics, Inc. (CLDI) filed a Form 8-K on March 27, 2026 to announce its financial results for the fourth quarter and full year ended December 31, 2025 and certain recent corporate developments. The company furnished a press release (dated March 27, 2026) as Exhibit 99.1 to the 8-K; the press release contains the detailed earnings and operational information. The 8-K also includes a Regulation FD disclosure.

Key Details

• Filing date: March 27, 2026 (Form 8-K).
• Reporting period: fourth quarter and full year ended December 31, 2025.
• Press release: furnished as Exhibit 99.1 to the 8-K (dated March 27, 2026).
• Items reported on the Form 8-K: Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure).

Why It Matters
This filing provides investors with the company’s latest quarterly and annual operating and financial results and alerts the market to any material updates covered in the press release. Because the 8-K furnishes the press release rather than restating full financial statements in the form, investors should review Exhibit 99.1 for the specific revenue, earnings or other metrics and watch for subsequent SEC filings (e.g., Form 10-K) for audited financial statements and additional context. The Regulation FD disclosure indicates the company is broadly sharing material information to ensure fair public access.